Metacrine is a privately-held biotechnology company headquartered in San Diego, CA. The company is focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases originated at the Salk Institute for Biological Studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/05/15 | $36,000,000 | Series A |
ARCH Venture Partners EcoR1 Capital Polaris Partners VenBio | undisclosed |
| 12/07/17 | $22,000,000 | Series B |
Alexandria Venture Investments ARCH Venture Partners Polaris Partners VenBio | undisclosed |
| 06/08/18 | $65,000,000 | Series C |
Alexandria Real Estate Equities ARCH Venture Partners ArrowMark Partners Deerfield Management Company, L.P. Franklin Templeton Invus Lilly Asia Ventures Polaris Partners VenBio Venrock  Vivo Capital | undisclosed |
